Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
291.37
-1.80 (-0.61%)
At close: Jun 26, 2026, 4:00 PM EDT
291.14
-0.23 (-0.08%)
After-hours: Jun 26, 2026, 6:19 PM EDT
Alnylam Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 29 analysts polled by S&P Global, Alnylam Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $436.32. The average 1-year stock price forecast is 49.75% higher than the current stock price, while the lowest is $310 (+6.39%) and the highest is $550 (+88.76%).
Price Target: $436.32 (+49.75%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Alnylam Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 15 | 14 | 14 | 15 | 14 |
| Buy | 6 | 6 | 6 | 6 | 7 | 7 |
| Hold | 8 | 7 | 8 | 8 | 8 | 8 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 28 | 28 | 28 | 28 | 30 | 29 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Buy Maintains $550 | Buy | Maintains | $550 | +88.76% | Jun 26, 2026 |
| Truist Financial | Truist Financial | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jun 26, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $500 | Buy | Reiterates | $500 | +71.60% | Jun 25, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $370 | Hold | Maintains | $370 | +26.99% | Jun 24, 2026 |
| Needham | Needham | Buy Maintains $510 | Buy | Maintains | $510 | +75.04% | Jun 24, 2026 |
Financial Forecast
Revenue This Year
5.63B
from 3.71B
Increased by 51.48%
Revenue Next Year
7.32B
from 5.63B
Increased by 30.19%
EPS This Year
9.50
from 5.08
Increased by 87.11%
EPS Next Year
13.77
from 9.50
Increased by 44.82%
EPS and Forward PE are based on non-GAAP adjusted numbers.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 6.1B | ||
| Avg | 5.6B | ||
| Low | 5.5B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 64.7% | ||
| Avg | 51.5% | ||
| Low | 47.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 13.00 | ||
| Avg | 9.50 | ||
| Low | 7.94 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 155.9% | ||
| Avg | 87.1% | ||
| Low | 56.3% |